Kaufman Rossin Wealth LLC Buys New Shares in Illumina, Inc. $ILMN

Key Points

• Kaufman Rossin Wealth LLC has invested approximately $364,000 in Illumina, Inc., acquiring 4,589 shares in the first quarter of the year.
• Illumina's shares have been the subject of multiple rating changes, with analysts raising target prices significantly; the current consensus rating is "Hold" with a target price of $124.58.
• The company reported an EPS of $1.19 for the last quarter, exceeding expectations, but its revenue decreased by 4.8% year-over-year.

Kaufman Rossin Wealth LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,589 shares of the life sciences company's stock, valued at approximately $364,000.

Several other large investors have also bought and sold shares of the business. Moors & Cabot Inc. lifted its holdings in Illumina by 2.5% in the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company's stock valued at $465,000 after buying an additional 145 shares during the period. Tokio Marine Asset Management Co. Ltd. raised its holdings in Illumina by 3.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company's stock worth $445,000 after purchasing an additional 164 shares during the period. Probity Advisors Inc. raised its holdings in Illumina by 12.2% in the fourth quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company's stock worth $274,000 after purchasing an additional 224 shares during the period. Xponance Inc. raised its holdings in Illumina by 1.0% in the first quarter. Xponance Inc. now owns 26,762 shares of the life sciences company's stock worth $2,123,000 after purchasing an additional 264 shares during the period. Finally, Rakuten Securities Inc. raised its holdings in Illumina by 290.3% in the first quarter. Rakuten Securities Inc. now owns 363 shares of the life sciences company's stock worth $29,000 after purchasing an additional 270 shares during the period. 89.42% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Robert W. Baird increased their target price on shares of Illumina from $84.00 to $105.00 and gave the stock a "neutral" rating in a report on Monday, July 28th. Daiwa America lowered shares of Illumina from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 12th. Morgan Stanley increased their target price on shares of Illumina from $100.00 to $105.00 and gave the stock an "equal weight" rating in a report on Monday, August 4th. Citigroup lowered shares of Illumina from a "hold" rating to a "strong sell" rating and cut their target price for the stock from $85.00 to $80.00 in a report on Wednesday, July 9th. Finally, Piper Sandler cut their target price on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. Seven investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Illumina has a consensus rating of "Hold" and a consensus target price of $124.58.

Illumina Stock Up 2.5%

Shares of ILMN stock traded up $2.51 during trading hours on Friday, hitting $101.80. 1,964,101 shares of the company were exchanged, compared to its average volume of 1,883,205. The business has a 50 day moving average of $98.18 and a two-hundred day moving average of $88.88. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.66. Illumina, Inc. has a 52 week low of $68.70 and a 52 week high of $156.66. The company has a market capitalization of $15.65 billion, a PE ratio of 12.89, a PEG ratio of 2.29 and a beta of 1.37.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a net margin of 29.36% and a return on equity of 28.93%. The company had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the prior year, the firm earned $0.36 earnings per share. The firm's revenue was down 4.8% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. Analysts anticipate that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.